| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4006335 | American Journal of Ophthalmology | 2007 | 20 Pages |
Abstract
This OCT-guided, variable-dosing regimen with ranibizumab resulted in visual acuity outcomes similar to the Phase III clinical studies, but required fewer intravitreal injections. OCT appears useful for determining when retreatment with ranibizumab is necessary.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Anne E. Fung, Geeta A. Lalwani, Philip J. Rosenfeld, Sander R. Dubovy, Stephan Michels, William J. Feuer, Carmen A. Puliafito, Janet L. Davis, Harry W. Jr, Maria Esquiabro,